Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSE:EBS NASDAQ:FGEN NASDAQ:PTCT NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$18.31-2.9%$15.79$9.57▼$30.41$2.53B0.931.86 million shs1.45 million shsEBSEmergent Biosolutions$7.34+0.1%$6.35$4.02▼$15.10$398.40M2.091.71 million shs1.04 million shsFGENFibroGen$7.15-2.7%$6.99$4.50▼$38.25$28.89M0.7476,039 shs59,778 shsPTCTPTC Therapeutics$48.55-2.0%$48.11$29.02▼$58.38$3.85B0.5871,724 shs759,887 shsZLABZai Lab$32.73-4.0%$34.06$16.01▼$44.34$3.64B0.991.02 million shs1.02 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-0.11%+12.40%+11.14%+59.97%-29.68%EBSEmergent Biosolutions+0.83%+4.86%+8.83%+67.70%-21.10%FGENFibroGen+18.74%+29.17%-4.92%+6.06%-67.46%PTCTPTC Therapeutics+1.60%+1.54%-4.29%+15.22%+55.87%ZLABZai Lab-4.43%-6.45%-14.80%+15.37%+99.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.7421 of 5 stars3.42.00.03.41.82.50.0EBSEmergent Biosolutions4.3071 of 5 stars3.51.00.04.62.12.51.3FGENFibroGen4.6393 of 5 stars3.33.00.04.73.83.30.6PTCTPTC Therapeutics4.2989 of 5 stars4.31.00.04.41.50.81.3ZLABZai Lab3.2747 of 5 stars3.45.00.00.02.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.75Moderate Buy$43.71138.75% UpsideEBSEmergent Biosolutions 3.00Buy$14.3395.28% UpsideFGENFibroGen 2.50Moderate Buy$250.003,396.50% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0033.88% UpsideZLABZai Lab 2.80Moderate Buy$54.2865.83% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, ZLAB, PTCT, FGEN, and EBS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025ZLABZai LabLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$73.00 ➝ $75.006/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$250.00 ➝ $250.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$545.21M4.64N/AN/A$1.54 per share11.89EBSEmergent Biosolutions$930.30M0.43$1.92 per share3.82$8.91 per share0.82FGENFibroGen$29.62M0.98N/AN/A($50.89) per share-0.14PTCTPTC Therapeutics$806.78M4.77N/AN/A($14.24) per share-3.41ZLABZai Lab$398.99M9.11N/AN/A$7.68 per share4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/A22.21N/A-45.33%-12.49%8/6/2025 (Estimated)EBSEmergent Biosolutions-$190.60M-$2.71N/A3.55N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)FGENFibroGen-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.46N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)ZLABZai Lab-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/7/2025 (Estimated)Latest ARWR, ZLAB, PTCT, FGEN, and EBS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025EBSEmergent Biosolutions$0.21N/AN/AN/A$148.55 millionN/A8/5/2025Q2 2025FGENFibroGen-$0.09N/AN/AN/A$2.88 millionN/A8/5/2025Q2 2025ZLABZai Lab-$0.42N/AN/AN/A$125.66 millionN/A5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/12/2025Q1 2025FGENFibroGen$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million5/7/2025Q1 2025EBSEmergent Biosolutions$0.49$0.71+$0.22$1.19$218.50 million$222.20 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.315.155.15EBSEmergent Biosolutions1.206.323.51FGENFibroGenN/A2.021.98PTCTPTC TherapeuticsN/A3.893.85ZLABZai LabN/A3.263.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%EBSEmergent Biosolutions78.40%FGENFibroGen72.71%PTCTPTC TherapeuticsN/AZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%EBSEmergent Biosolutions1.20%FGENFibroGen3.07%PTCTPTC Therapeutics5.50%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.10 million132.16 millionOptionableEBSEmergent Biosolutions2,42054.28 million53.63 millionOptionableFGENFibroGen5704.04 million3.92 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableZLABZai Lab1,869111.08 million105.57 millionOptionableARWR, ZLAB, PTCT, FGEN, and EBS HeadlinesRecent News About These CompaniesZai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025July 10 at 8:01 AM | businesswire.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?July 8 at 12:12 PM | marketbeat.com67,159 Shares in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Bought by Penserra Capital Management LLCJuly 8 at 5:37 AM | marketbeat.comPrincipal Financial Group Inc. Purchases 1,121,856 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 5, 2025 | marketbeat.comBrokerages Set Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Target Price at $54.28July 5, 2025 | americanbankingnews.comZai Lab FY2025 EPS Estimate Decreased by Cantor FitzgeraldJuly 4, 2025 | americanbankingnews.comYing Du Sells 7,072 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) StockJuly 3, 2025 | marketbeat.comCantor Fitzgerald Lowers Earnings Estimates for Zai LabJuly 3, 2025 | marketbeat.comFY2026 EPS Estimates for Zai Lab Raised by Leerink PartnrsJuly 3, 2025 | americanbankingnews.comLeerink Partnrs Analysts Lift Earnings Estimates for Zai LabJuly 2, 2025 | marketbeat.comInsider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of StockJuly 2, 2025 | insidertrades.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in StockJuly 1, 2025 | marketbeat.comAmgen and Zai Lab’s trial of gastric cancer therapy meets primary endpointJuly 1, 2025 | finance.yahoo.comAmgen, Zai Lab succeed in gastric cancer studyJune 30, 2025 | msn.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 30, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Price Target Raised to $75.00 at Leerink PartnersJune 30, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?June 30, 2025 | marketbeat.comZai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric CancerJune 30, 2025 | businesswire.comOppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)June 30, 2025 | marketbeat.comZai Lab (ZLAB) chief legal officer sells $212k in sharesJune 29, 2025 | investing.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $96,647.75 in StockJune 28, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARWR, ZLAB, PTCT, FGEN, and EBS Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$18.31 -0.55 (-2.92%) Closing price 04:00 PM EasternExtended Trading$18.27 -0.04 (-0.22%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Emergent Biosolutions NYSE:EBS$7.34 +0.01 (+0.14%) Closing price 03:59 PM EasternExtended Trading$7.25 -0.09 (-1.23%) As of 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.FibroGen NASDAQ:FGEN$7.15 -0.20 (-2.72%) Closing price 04:00 PM EasternExtended Trading$7.32 +0.17 (+2.31%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.PTC Therapeutics NASDAQ:PTCT$48.55 -0.97 (-1.96%) Closing price 04:00 PM EasternExtended Trading$48.14 -0.41 (-0.84%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Zai Lab NASDAQ:ZLAB$32.73 -1.35 (-3.96%) Closing price 04:00 PM EasternExtended Trading$32.74 +0.01 (+0.02%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
